Keros Therapeutics Stock Options Expiring on 21st of March
| KROS Stock | USD 11.43 0.28 2.39% |
Keros Therapeutics' latest option contracts expiring on March 21st 2025 are carrying combined implied volatility of 2.42 with a put-to-call open interest ratio of 0.39 over 41 outstanding agreements suggesting investors are buying way more calls than puts on contracts expiring on March 21st 2025. The total put volume is at 201, with calls trading at the volume of 408. This yields a 0.49 put-to-call volume ratio.
Open Interest Against March 21st 2025 Option Contracts
Keros Therapeutics option prices can potentially be used to forecast stock returns because most option chains provide information not only about the current prices but also about the future conditions in Keros Therapeutics' lending market. For example, when Keros Therapeutics' puts are not actively trading or completely missing in the marketplace, investors can use it to internalize expected shorting costs. So if an investor is writing a put option on Keros Therapeutics, he or she must hedge the risk by shorting Keros Therapeutics stock over its option's life.
2025-03-21
The chart above shows Keros Therapeutics' distribution of open interest by maturity on contracts that have not yet been settled. The area between the two highest points is the projection of the price at expiration. Keros Therapeutics' open interest chart also provides vital information regarding the liquidity of an option. If there is no open interest for Keros Therapeutics' option, there is no secondary market available for investors to trade.
Keros Therapeutics Maximum Pain Price Across 2025-03-21 Option Contracts
Max pain occurs when Keros Therapeutics' market makers reach a net positive position across all Keros Therapeutics' options at a strike price where option holders stand to lose the most money. By contrast, Keros Therapeutics' option sellers may reap the most after selling more options than buying, causing them to expire worthless.
Keros Therapeutics In The Money Call Balance
When Keros Therapeutics' strike price is surpassing the current stock price, the option contract against Keros Therapeutics stock is said to be in the money. When it comes to buying Keros Therapeutics' options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
While 'out-of-the-money' option contracts written on Keros Therapeutics are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.
Keros Current Options Market Mood
Keros Therapeutics' open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps Keros Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.
Put-to-Call Open Interest
Put-to-Call Volume
Unfortunately, most Keros Therapeutics' options investors are not very successful. Keros Therapeutics' option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction.
Rule 16 of the current Keros contract
Base on the Rule 16, the options market is currently suggesting that Keros Therapeutics will have an average daily up or down price movement of about 0.15% per day over the life of the 2025-03-21 option contract. With Keros Therapeutics trading at USD 11.43, that is roughly USD 0.0173. If you think that the market is fully incorporating Keros Therapeutics' daily price movement you should consider buying Keros Therapeutics options at the current volatility level of 2.42%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Keros |
Keros Therapeutics Option Chain
When Keros Therapeutics' strike price is surpassing the current stock price, the option contract against Keros Therapeutics stock is said to be in the money. When it comes to buying options that are ITM or OTM, the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
Keros Therapeutics' option chain is a display of a range of information that helps investors for ways to trade options on Keros. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for Keros. It also shows strike prices and maturity days for a Keros Therapeutics against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone. | Open Int | Strike Price | Current Spread | Last Price | |||
Call | KROS250321C00010000 | 7 | 10.0 | 2.1 - 2.85 | 2.4 | In |
Call | KROS250321C00012500 | 768 | 12.5 | 0.95 - 1.35 | 1.3 | Out |
Call | KROS250321C00015000 | 834 | 15.0 | 0.45 - 0.7 | 0.75 | Out |
Call | KROS250321C00017500 | 38 | 17.5 | 0.0 - 0.4 | 0.4 | Out |
Call | KROS250321C00020000 | 48 | 20.0 | 0.0 - 0.25 | 0.25 | Out |
Call | KROS250321C00022500 | 525 | 22.5 | 0.05 - 0.55 | 0.15 | Out |
Call | KROS250321C00025000 | 34 | 25.0 | 0.0 - 0.25 | 0.2 | Out |
Call | KROS250321C00030000 | 426 | 30.0 | 0.0 - 1.65 | 0.4 | Out |
Call | KROS250321C00035000 | 4 | 35.0 | 0.0 - 4.8 | 0.73 | Out |
Call | KROS250321C00040000 | 101 | 40.0 | 0.0 - 0.05 | 0.01 | Out |
Call | KROS250321C00045000 | 2 | 45.0 | 0.0 - 4.8 | 0.57 | Out |
Call | KROS250321C00060000 | 5 | 60.0 | 0.0 - 4.8 | 10.0 | Out |
Call | KROS250321C00065000 | 0 | 65.0 | 0.0 - 4.8 | 4.0 | |
Call | KROS250321C00070000 | 1 | 70.0 | 0.0 - 4.8 | 4.4 | Out |
Call | KROS250321C00075000 | 0 | 75.0 | 0.0 - 4.8 | 4.8 | |
Call | KROS250321C00080000 | 1 | 80.0 | 0.0 - 4.8 | 4.2 | Out |
Call | KROS250321C00085000 | 0 | 85.0 | 0.0 - 1.4 | 1.4 | |
Call | KROS250321C00090000 | 1 | 90.0 | 0.0 - 1.45 | 0.15 | Out |
Call | KROS250321C00095000 | 0 | 95.0 | 0.0 - 1.45 | 1.45 | |
Call | KROS250321C00100000 | 1 | 100.0 | 0.0 - 1.45 | 0.1 | Out |
Call | KROS250321C00105000 | 0 | 105.0 | 0.0 - 1.45 | 1.45 | |
Put | KROS250321P00007500 | 102 | 7.5 | 0.0 - 0.7 | 0.57 | Out |
Put | KROS250321P00010000 | 679 | 10.0 | 0.55 - 0.7 | 0.6 | Out |
Put | KROS250321P00012500 | 269 | 12.5 | 1.45 - 2.3 | 1.8 | In |
Put | KROS250321P00015000 | 19 | 15.0 | 3.2 - 4.1 | 5.0 | In |
Put | KROS250321P00017500 | 6 | 17.5 | 4.9 - 7.0 | 4.3 | In |
Put | KROS250321P00020000 | 1 | 20.0 | 6.2 - 8.9 | 4.6 | In |
Put | KROS250321P00022500 | 2 | 22.5 | 10.2 - 11.4 | 6.0 | In |
Put | KROS250321P00025000 | 1 | 25.0 | 12.7 - 15.0 | 8.62 | In |
Put | KROS250321P00045000 | 4 | 45.0 | 32.7 - 34.3 | 27.3 | In |
Put | KROS250321P00055000 | 3 | 55.0 | 41.5 - 45.1 | 6.7 | In |
Put | KROS250321P00060000 | 2 | 60.0 | 46.4 - 50.2 | 41.39 | In |
Put | KROS250321P00065000 | 0 | 65.0 | 52.4 - 54.2 | 52.4 | In |
Put | KROS250321P00070000 | 0 | 70.0 | 56.7 - 60.0 | 15.3 | In |
Put | KROS250321P00075000 | 0 | 75.0 | 61.4 - 65.3 | 61.4 | In |
Put | KROS250321P00080000 | 0 | 80.0 | 66.2 - 70.3 | 66.2 | In |
Put | KROS250321P00085000 | 0 | 85.0 | 71.5 - 74.8 | 71.5 | In |
Put | KROS250321P00090000 | 0 | 90.0 | 76.4 - 80.3 | 76.4 | In |
Put | KROS250321P00095000 | 0 | 95.0 | 81.5 - 84.4 | 81.5 | In |
Put | KROS250321P00100000 | 0 | 100.0 | 86.5 - 88.9 | 86.5 | In |
Put | KROS250321P00105000 | 0 | 105.0 | 91.3 - 95.3 | 91.3 | In |
Keros Therapeutics Market Cap Over Time
Market Cap |
| Timeline |
Keros Total Stockholder Equity
Total Stockholder Equity |
|
Keros Therapeutics Corporate Management
| Robin Wagner | Senior Resources | Profile | |
| Simon MBBS | Chief Officer | Profile | |
| Keith MBA | Chief Officer | Profile | |
| Christopher MSc | Chief Officer | Profile | |
| John MBA | Senior Management | Profile | |
| Jennifer Lachey | Chief Officer | Profile | |
| Jasbir Seehra | CEO and President | Profile |
Additional Tools for Keros Stock Analysis
When running Keros Therapeutics' price analysis, check to measure Keros Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Keros Therapeutics is operating at the current time. Most of Keros Therapeutics' value examination focuses on studying past and present price action to predict the probability of Keros Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Keros Therapeutics' price. Additionally, you may evaluate how the addition of Keros Therapeutics to your portfolios can decrease your overall portfolio volatility.